



## Sciences de la vie

Compte tenu de la multitude de défis juridiques auxquels sont confrontés nos clients de ce secteur, il est pour nous essentiel de diversifier les compétences que nous développons. Notre équipe spécialisée dans les sciences de la vie réunit des avocats dotés de connaissances juridiques, scientifiques et médicales qui comprennent précisément la complexité du métier et des cadres réglementaires dans lesquels nos clients exercent leurs activités.

Les défis auxquels sont aujourd'hui confrontées les entreprises biopharmaceutiques et d'équipement médical n'ont jamais été aussi importants. Pour que ces entreprises accompagnent des thérapies prometteuses, depuis la recherche en laboratoire jusqu'à la mise sur le marché, elles doivent les protéger contre les risques de propriété intellectuelle, de changement réglementaire et de réputation. Ces dernières années, la pression s'est par ailleurs accentuée à plusieurs égards : demande des actionnaires en retours sur investissement plus importants, perte de sources de revenu considérables du fait de l'expiration de brevets ou des problématiques posées par les génériques, âpre compétition dans des domaines clés de la thérapie, pressions sur les prix de la part des débiteurs des dépenses de santé, réglementation publique lourde dépassant les questions essentielles de sécurité, hausse des coûts de R&D, défis posés par l'optimisation des retours sur investissement sur les marchés émergents et mesures agressives d'application des peines par les pouvoirs publics.

Notre équipe dédiée aux sciences de la vie compte parmi les plus importantes et les plus actives au monde. Agissant comme une équipe unique dans plus de 30 juridictions, nous associons une expérience de terrain à des connaissances approfondies de ce secteur d'activité, à savoir les problématiques scientifiques, médicales, réglementaires, commerciales et relatives à l'exécution des décisions de justice, auxquelles sont confrontés nos clients spécialisés dans l'industrie biopharmaceutique, les équipements médicaux et les diagnostics.

Notre équipe, composée d'avocats reconnus pour la qualité de leur pratique, intervient en matière de contentieux, de conformité et d'enquêtes, de stratégie de protection et d'application des droits de propriété intellectuelle, de fusions & acquisitions, de concessions de licence et de distribution, de conseils en essais cliniques, de

### CONTACTS CLÉS

#### Marco de Morpurgo

Partner  
Rome  
T: +39 06 68 880 1  
[email protected]

#### Andrew P. Gilbert

Partner  
New Jersey (Short Hills)  
T: +1 973 520 2553  
[email protected]

#### Matt Holian

Partner  
Boston  
T: +1 617 406 6009  
[email protected]

### AUTRES COMPÉTENCES

- Corporate
- Employment
- Intellectual Property and Technology
- Litigation, Arbitration and Investigations
- Real Estate
- Tax

confidentialité, d'externalisation, ainsi qu'en droit des sociétés et de la concurrence. Nous accompagnons également nos clients dans tous les autres domaines nécessaires à une gestion réussie des risques, tels que les affaires gouvernementales, l'environnement, la fiscalité à l'import/export, l'immobilier et le droit social. La plupart de nos avocats sont d'anciens professionnels du secteur, disposent d'un doctorat ou d'autres diplômes d'enseignement supérieur en sciences de la vie, ou sont d'anciens fonctionnaires ou magistrats.

Conscients de la diversité des besoins de notre clientèle, nous composons et adaptons sans délai des équipes dédiées au service de nos clients, qu'il s'agisse de groupes pharmaceutiques internationaux, d'entreprises d'équipements médicaux de taille moyenne ou de start-up spécialisées dans les biotechnologies. Nos équipes bénéficient du soutien de nos avocats partout dans le monde afin de répondre efficacement aux exigences du dossier concerné, tant pour les opérations internationales et les enquêtes/contentieux, que les projets de conseils transfrontaliers.

Nos logiciels de pointe en ressources humaines, budget et facturation, créés spécifiquement pour assister nos clients internationaux du secteur des sciences de la vie, permettent à nos équipes d'apporter une vraie valeur ajoutée aux résultats exceptionnels obtenus.

Notre équipe spécialisée dans les sciences de la vie accompagne les entreprises et les aide à résoudre leurs principaux défis au quotidien. Quelques exemples de notre expérience:

- Conduite d'une enquête sensible en Chine
- Négociation d'une opération complexe de distribution dans plusieurs pays d'Amérique latine
- Intervention en qualité d'avocat national dans une procédure de masse en responsabilité quasi délictuelle aux États-Unis
- Assistance à la cession ou l'acquisition d'un actif d'entreprise essentiel
- Conseils sur la mise en œuvre de lois sur la transparence ou sur l'impact de toute autre nouvelle législation
- Conception d'un programme de réduction des risques pour un produit vedette
- Négociation d'un important contrat de vaccin avec une ONG internationale
- Conseils sur des essais cliniques multi juridictionnels
- Conseil sur une réduction d'effectifs en Europe
- Accompagnement des fonctions de conduite des activités internationales et de conformité
- Externalisation essentielle des fonctions R&D ou informatiques
- Conception d'une stratégie de propriété intellectuelle pour une nouvelle thérapie prometteuse
- Négociation d'un accord international de concession de licence et de collaboration
- Protection d'un médicament vedette dans une action en contrefaçon de brevet

## ACTUALITÉS

---

### Publications

#### **The Russian Supreme Court clarifies intellectual property legislation**

30 Sep 2019

Clarifications from the Supreme Court have a significant impact on the further development of court practice in Russia.

---

#### **ITC Section 337 update: Expect heavy emphasis on public interest in pharma/medical device investigations**

30 Sep 2019

Difficult public interest issues may arise when a potentially life-saving drug or medical device is sought to be excluded.

---

---

## **The CBD problem: searching for a legal pathway for CBD in foods and supplements**

20 September 2019

The current state of the laws and regulations in the US, and potential pathways to a resolution.

---

## **Treasury Department proposes regulations comprehensively implementing FIRRMA and reforming CFIUS national security review**

19 September 2019

The proposed regulations affect non-controlling investments involving critical technologies, critical infrastructure, and sensitive personal data; and transactions involving real estate near sensitive national security facilities.

---

## **Israel Group News August 2019**

7 August 2019

### **[ISRAEL GROUP NEWS](#)**

In this issue, our global activities, latest publications, coming events and more.

---

## **ITC Section 337 update: Commission decision stayed?**

24 July 2019

Significant new developments.

---

## **Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods**

10 July 2019

On 20 June 2019, for the first time, the German Federal Joint Committee (FJC – Gemeinsamer Bundesausschuss / G-BA), the highest decision-making body of the joint self-government of physicians, dentists, hospitals and statutory health insurance funds (SHI – gesetzliche Krankenversicherung / GKV) in Germany, made the resolution that a specific biomarker-based test to support the treatment decision for or against adjuvant chemotherapy, i. e. after primary surgery, in certain breast cancer patients may be reimbursed by the SHIs.

---

## **Intellectual Property and Technology News (Asia Pacific) May 2019**

15 MAY 2019

### **[INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES](#)**

Intellectual Property and Technology News (Asia Pacific) is our biannual publication designed to report on worldwide development in intellectual property and technology law, offering perspectives, analysis and visionary ideas.

---

---

## Israel Group News May 2019

9 MAY 2019

### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, coming events and more.

---

## EU Policy & Regulatory Alert - EU Publishes Artificial Intelligence Ethics Guidelines

12 APR 2019

On 8 April 2019, the EU's High-Level Expert Group ("AI HLEG") on Artificial Intelligence ("AI") published the much-anticipated "Ethics Guidelines for Trustworthy AI", setting out a horizontal framework for the development and deployment of ethical and robust AI systems across the EU

---

## Supreme Court Corner Q1 2019

11 APR 2019

In celebration of the 10th anniversary of IPT News, we note that 10 years ago, in the first quarter of 2009, Bernard L. Bilski filed his petition in the landmark *Bilski v. Kappos*, 561 U.S. 593 (2010), forever shaping the patentability of business methods.

---

## EU Policy & Regulatory Alert: EU Mechanism for Foreign Investment Screening to Enter into Force in April

21 MAR 2019

Today, on 21 March 2019, the new Regulation establishing a framework for the screening of foreign direct investments into the Union was published in the Official Journal of the European Union (EU).

---

## Top of Mind: Litigation

20 MAR 2019

In this issue, our coverage of 10 big topics businesses have been thinking about this quarter.

---

## PFAS: in California, regulators put cleanup levels on hold, but announce major data hunt

7 MAR 2019

This data hunt will affect thousands of facilities, drinking water systems and private drinking water well owners.

---

## Explainability: where AI and liability meet

25 FEB 2019

Makers and users of AI face a new and interesting problem: what is the acceptable tradeoff between explanation and accuracy?

---

## Israel Group News

---

12 FEB 2019

## [ISRAEL GROUP NEWS](#)

In this issue, the rise of the Data Protection Officer, plus news and coming events.

---

### **EU Policy & Regulatory Update - EU Adds Three Iranian Persons to EU Terrorist List**

14 JAN 2019

On 8 January 2019, the Council of the European Union (EU) adopted Decision (CFSP) 2019/25 amending and updating the list of persons, groups and entities subject to Articles 2, 3 and 4 of Common Position 2001/931/CFSP.

---

### **Relying on "common sense" instead of prior art in evaluating the obviousness of pharmaceutical patents**

21 DEC 2018

A one-time aberration, or the start of a trend?

---

### ***Alice* in Wonderland: navigating the strange world of patenting AI**

21 DEC 2018

Like the bottle labeled DRINK ME, certain techniques can make the trip through the AI-patent rabbit hole more scalable.

---

### **Leading life science patent litigators join DLA Piper in New York**

21 DEC 2018

Michael Dougherty and Tony Pezzano have joined the firm's Intellectual Property and Technology practice as patent litigation partners in New York.

---

### **Top of mind: Litigation**

10 DEC 2018

Our coverage of big compliance, enforcement and litigation issues that businesses are thinking about this quarter.

---

### **Israel Group News**

24 OCT 2018

## [ISRAEL GROUP NEWS](#)

In this issue, legal developments worldwide that affect this dynamic ecosystem.

---

### **CFIUS pilot program mandates declarations for certain non-controlling investments in critical technologies**

17 OCT 2018

The pilot program covers critical technologies in 27 industries.

---

### **Section 301 additional tariffs on imports of Chinese products: options for high tech and manufacturing companies**

3 OCT 2018

Additional tariffs of 10 percent or 25 percent have been imposed on three different lists of thousands of imports from China. Companies can request exclusion from these tariffs.

---

### **Supreme Court Corner Q3 2018**

27 SEP 2018

The court rules on recovery of lost foreign profits and ponders patentability issues in an invention's sale to a third party that is obligated to keep the invention confidential.

---

### **Intellectual Property and Technology News (Asia Pacific) September 2018**

27 SEP 2018

#### **[INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES](#)**

Intellectual Property and Technology News (Asia Pacific) is our annual publication designed to report on worldwide developments in intellectual property and technology law, offering perspectives, analysis and visionary ideas.

---

### **The tide turns: If your company is doing business in the US, it may soon be required to collect state sales taxes**

24 JUL 2018

Companies selling online products and services to customers in US states may soon be required to register, collect and remit taxes in those states.

---

### **eSignature and ePayment News and Trends**

23 JUL 2018

#### **[ESIGNATURE AND EPAYMENT NEWS AND TRENDS](#)**

This regular publication from DLA Piper aims to help companies identify significant news and legal developments impacting digital transactions.

---

### **eSignature and ePayment News and Trends**

29 JUN 2018

#### **[ESIGNATURE AND EPAYMENT NEWS AND TRENDS](#)**

In this issue, is your website ADA compliant? Plus news on federal and state law, federal and state regulatory activities, fresh judicial precedent and more.

---

---

## Is your website ADA compliant? A brief look at the current legal status

29 JUN 2018

Websites too face regulatory issues around compliance with the Americans with Disabilities Act and other rules involving accessibility and accommodation.

---

## Pharmaceutical Trademarks 2018/2019 - Chapter: France

5 APR 2018

Like all trademarks, pharmaceutical trademarks are subject to general trademark rules regarding validity and use. Until recently, both French and European law required a trademark to be capable of graphical representation. This requirement allowed the registration of shapes, colours and sounds, but excluded signs such as smells. The European trademark law reform, comprising EU Directive 2015/2436 and the EU Trademark Regulation (2017/1001), deleted the graphical representation requirement from trademark law. This change marks a dramatic step forward in trademark law and could make it easier to register smells and other non-traditional trademarks.

---

## Regulation of medical devices - what is changing?

13 MAR 2018

After four years of deliberations, the new Medical Devices Regulation finally came into effect on 25 May 2017. This marks the commencement of a three-year transitional period for manufacturers of medical devices to update their policies and processes in order to distribute products in the EU market.

---

## Global Data Privacy Snapshot 2018: How does your organisation compare?

31 JAN 2018

Data protection is rising on the agenda globally: the past year has seen China introduce the PRC Cybersecurity Law, the introduction of Australia's mandatory Privacy Amendment (Notifiable Data Breaches) Act 2017, while the EU's long awaited General Data Protection Regulation is due to come in to force in May 2018.

---

## 2018 outlook for drugs and medical devices in China: regulatory reform fueled by innovation

18 JAN 2018

The year 2017 ended with a central government directive to reform the regulatory approval system for drugs and medical devices and a subsequent flood of CFDA changes and proposed changes to the system, and we should see further regulatory reform in 2018 as the Chinese government continues to encourage domestic innovation in this sector.

---

## Intellectual Property and Technology News (Asia Pacific) December 2017

7 DEC 2017

### [INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES](#)

Intellectual Property and Technology News (Asia Pacific) is our biannual publication designed to report on worldwide developments

---

in intellectual property and technology law, offering perspectives, analysis and visionary ideas.

---

## **Intellectual Property and Technology News (United States), Issue 23, Q3 2014**

10 SEP 2014

### **INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES**

Our Intellectual Property and Technology News reports on worldwide developments in IP and technology law, offering perspectives, analysis and visionary ideas.

---

## **Distributing patent rights between affiliates: guidelines to support enforcement rights around the world**

16 NOV 2015

Considering a few issues at the outset when rights are distributed between Parent and Affiliate (or between multiple affiliates) may avoid difficulties in the future when a company wants to enforce patent rights.

---

## **EVÈNEMENTS**

### **Récemment**

#### **TopCo liability panel**

25 JUN 2019

London

---

#### **New frontiers on the abuse of dominance**

18 JUN 2018

Webinar

---

#### **Enforcement and compliance trends in today's life sciences environment**

26 APR 2018

Webinar

---

## **NEWS**

---

### **DLA Piper announces launch of Artificial Intelligence practice**

14 MAY 2019

DLA Piper announced today the launch of its Artificial Intelligence practice, which will focus on assisting companies as they

---



navigate the legal landscape of emerging and disruptive technologies, while helping them understand the legal and compliance risks arising from the creation and deployment of AI systems.

---

### **DLA Piper announces partnership promotions for 2019**

1 APR 2019

DLA Piper is proud to announce that 77 lawyers have been promoted to its partnership. The promotions are effective as of April 1, 2019 in the United States and May 1, 2019 for EMEA and Asia Pacific. The promotions were made across many of the firm's practice areas in 43 different offices throughout 20 countries.

---

### **DLA Piper enhances cross-border tax capability with new partner hire in Dublin**

26 FEB 2019

DLA Piper today announces the appointment of Maura Dineen as a Tax partner in the firm's newly opened Dublin office. This is the fifth partner hire for DLA Piper in Dublin in a month, following the announcements in January of Conor Houlihan (Finance & Projects), Éanna Mellett (Corporate), Mark Rasdale (Intellectual Property & Technology) and Ciara McLoughlin (Employment).

---

### **DLA Piper recognized as a leading private equity, venture capital and M&A firm in *PitchBook's* league tables**

19 FEB 2019

For the second consecutive year, DLA Piper was the only firm to rank as one of the top five most active law firms for private equity, venture capital and M&A deal volume in *PitchBook's* 2018 global league tables report.

---

### **DLA Piper conseille la Société d'aménagement Zenata dans son partenariat emblématique avec Saudi German Hospital Group**

29 MAY 2018

DLA Piper a conseillé la Société d'Aménagement Zenata (SAZ), l'entité en charge de l'aménagement global de l'Eco-Cité Zenata au Maroc, dans le cadre de sa signature d'une convention de développement et de gestion du pôle santé avec le groupe Saudi German Hospital (SGH).

---

### **DLA Piper named International Law Firm of the Year in Ukraine for fifth year running at The Legal Awards 2018**

24 MAY 2018

DLA Piper has been named International Law Firm of the Year in Ukraine at the 2018 Legal Awards, held by Yuridicheskaya Practika Publishing House. This is the fifth time the office has won the award.

---

## **DLA Piper announces partnership promotions for 2018**

3 APR 2018

DLA Piper is proud to announce that 62 lawyers have been promoted to its partnership. The promotions are effective as of 1 April 2018 in the United States and 1 May 2018 for EMEA and Asia Pacific. The promotions were made across many of the firm's practice areas in 42 different offices throughout 20 countries.

---

## **Businesses still not fully aware of Data Protection issues**

31 JAN 2018

DLA Piper has released its second Data Privacy Snapshot report, finding that once again, company global privacy programs have gaps in meeting increasingly demanding global privacy principles. Significantly, it appears that many companies are falling short of data protection obligations under the General Data Protection Regulation (GDPR), which will start to apply from 25 May 2018.

---

## **Stephen Matthews joins DLA Piper's Litigation practice in New Jersey**

17 JAN 2018

DLA Piper announced today that Stephen Matthews has joined the firm's Litigation practice as a partner in the Short Hills, New Jersey, office.

---

## **DLA Piper advises Immunomedics on royalty funding and stock purchase agreements with Royalty Pharma which raised an aggregate of US\$250 million**

9 JAN 2018

DLA Piper represented Immunomedics, Inc., in the sale of tiered, sales-based royalty rights on global net sales of sacituzumab govitecan (IMMU-132) to Royalty Pharma for US\$175 million. Royalty Pharma has also purchased US\$75 million in common stock of Immunomedics, at US\$17.15 per share.

---

## **DLA Piper advises on the sale of shares in one of Egypt's fastest growing pharmaceutical companies**

9 NOV 2017

DLA Piper has advised Orchidia Pharmaceutical Industries (the "Company" or "Orchidia"), a leading ophthalmic generic medicine manufacturer and one of Egypt's fastest growing pharmaceutical companies, and Dr. Ossama Fouad Abbas, the founder, majority shareholder and Chairman of the Company, on the sale of a stake in the Company and two holding companies incorporated in Cyprus to Egyptian-American Enterprise Fund (EAEF).

---





## Sciences de la vie

Compte tenu de la multitude de défis juridiques auxquels sont confrontés nos clients de ce secteur, il est pour nous essentiel de diversifier les compétences que nous développons. Notre équipe spécialisée dans les sciences de la vie réunit des avocats dotés de connaissances juridiques, scientifiques et médicales qui comprennent précisément la complexité du métier et des cadres réglementaires dans lesquels nos clients exercent leurs activités.

Les défis auxquels sont aujourd'hui confrontées les entreprises biopharmaceutiques et d'équipement médical n'ont jamais été aussi importants. Pour que ces entreprises accompagnent des thérapies prometteuses, depuis la recherche en laboratoire jusqu'à la mise sur le marché, elles doivent les protéger contre les risques de propriété intellectuelle, de changement réglementaire et de réputation. Ces dernières années, la pression s'est par ailleurs accentuée à plusieurs égards : demande des actionnaires en retours sur investissement plus importants, perte de sources de revenu considérables du fait de l'expiration de brevets ou des problématiques posées par les génériques, âpre compétition dans des domaines clés de la thérapie, pressions sur les prix de la part des débiteurs des dépenses de santé, réglementation publique lourde dépassant les questions essentielles de sécurité, hausse des coûts de R&D, défis posés par l'optimisation des retours sur investissement sur les marchés émergents et mesures agressives d'application des peines par les pouvoirs publics.

Notre équipe dédiée aux sciences de la vie compte parmi les plus importantes et les plus actives au monde. Agissant comme une équipe unique dans plus de 30 juridictions, nous associons une expérience de terrain à des connaissances approfondies de ce secteur d'activité, à savoir les problématiques scientifiques, médicales, réglementaires, commerciales et relatives à l'exécution des décisions de justice, auxquelles sont confrontés nos clients spécialisés dans l'industrie biopharmaceutique, les équipements médicaux et les diagnostics.

Notre équipe, composée d'avocats reconnus pour la qualité de leur pratique, intervient en matière de contentieux, de conformité et d'enquêtes, de stratégie de protection et d'application des droits de propriété intellectuelle, de fusions & acquisitions, de concessions de licence et de distribution, de conseils en essais cliniques, de confidentialité, d'externalisation, ainsi qu'en droit des sociétés et de la concurrence. Nous accompagnons également nos clients dans tous les autres domaines nécessaires à une gestion réussie des risques, tels que les affaires gouvernementales, l'environnement, la fiscalité à l'import/export, l'immobilier et le droit social. La plupart de nos avocats sont d'anciens professionnels du secteur, disposent d'un doctorat ou d'autres diplômes d'enseignement supérieur en sciences de la vie, ou sont d'anciens fonctionnaires ou magistrats.

Conscients de la diversité des besoins de notre clientèle, nous composons et adaptons sans délai des équipes dédiées au service de nos clients, qu'il s'agisse de groupes pharmaceutiques internationaux, d'entreprises d'équipements médicaux de taille moyenne ou de start-up spécialisées dans les biotechnologies. Nos équipes bénéficient du soutien de nos avocats partout dans le monde afin de répondre efficacement aux exigences du dossier concerné, tant pour les opérations internationales et les enquêtes/contentieux, que les projets de conseils transfrontaliers.

Nos logiciels de pointe en ressources humaines, budget et facturation, créés spécifiquement pour assister nos clients

internationaux du secteur des sciences de la vie, permettent à nos équipes d'apporter une vraie valeur ajoutée aux résultats exceptionnels obtenus.

Notre équipe spécialisée dans les sciences de la vie accompagne les entreprises et les aide à résoudre leurs principaux défis au quotidien. Quelques exemples de notre expérience:

- Conduite d'une enquête sensible en Chine
- Négociation d'une opération complexe de distribution dans plusieurs pays d'Amérique latine
- Intervention en qualité d'avocat national dans une procédure de masse en responsabilité quasi délictuelle aux États-Unis
- Assistance à la cession ou l'acquisition d'un actif d'entreprise essentiel
- Conseils sur la mise en œuvre de lois sur la transparence ou sur l'impact de toute autre nouvelle législation
- Conception d'un programme de réduction des risques pour un produit vedette
- Négociation d'un important contrat de vaccin avec une ONG internationale
- Conseils sur des essais cliniques multi juridictionnels
- Conseil sur une réduction d'effectifs en Europe
- Accompagnement des fonctions de conduite des activités internationales et de conformité
- Externalisation essentielle des fonctions R&D ou informatiques
- Conception d'une stratégie de propriété intellectuelle pour une nouvelle thérapie prometteuse
- Négociation d'un accord international de concession de licence et de collaboration
- Protection d'un médicament vedette dans une action en contrefaçon de brevet

## ACTUALITÉS

---

### Publications

#### **The Russian Supreme Court clarifies intellectual property legislation**

30 Sep 2019

Clarifications from the Supreme Court have a significant impact on the further development of court practice in Russia.

---

#### **ITC Section 337 update: Expect heavy emphasis on public interest in pharma/medical device investigations**

30 Sep 2019

Difficult public interest issues may arise when a potentially life-saving drug or medical device is sought to be excluded.

---

#### **The CBD problem: searching for a legal pathway for CBD in foods and supplements**

20 September 2019

The current state of the laws and regulations in the US, and potential pathways to a resolution.

---

#### **Treasury Department proposes regulations comprehensively implementing FIRRMA and reforming CFIUS national security review**

19 September 2019

The proposed regulations affect non-controlling investments involving critical technologies, critical infrastructure, and sensitive

---

personal data; and transactions involving real estate near sensitive national security facilities.

---

## Israel Group News August 2019

7 August 2019

### [ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, coming events and more.

---

## ITC Section 337 update: Commission decision stayed?

24 July 2019

Significant new developments.

---

## Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019

On 20 June 2019, for the first time, the German Federal Joint Committee (FJC – Gemeinsamer Bundesausschuss / G-BA), the highest decision-making body of the joint self-government of physicians, dentists, hospitals and statutory health insurance funds (SHI – gesetzliche Krankenversicherung / GKV) in Germany, made the resolution that a specific biomarker-based test to support the treatment decision for or against adjuvant chemotherapy, i. e. after primary surgery, in certain breast cancer patients may be reimbursed by the SHIs.

---

## Intellectual Property and Technology News (Asia Pacific) May 2019

15 MAY 2019

### [INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES](#)

Intellectual Property and Technology News (Asia Pacific) is our biannual publication designed to report on worldwide development in intellectual property and technology law, offering perspectives, analysis and visionary ideas.

---

## Israel Group News May 2019

9 MAY 2019

### [ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, coming events and more.

---

## EU Policy & Regulatory Alert - EU Publishes Artificial Intelligence Ethics Guidelines

12 APR 2019

On 8 April 2019, the EU's High-Level Expert Group ("AI HLEG") on Artificial Intelligence ("AI") published the much-anticipated "Ethics Guidelines for Trustworthy AI", setting out a horizontal framework for the development and deployment of ethical and robust AI systems across the EU

---

## Supreme Court Corner Q1 2019

11 APR 2019

In celebration of the 10th anniversary of IPT News, we note that 10 years ago, in the first quarter of 2009, Bernard L. Bilski filed his petition in the landmark *Bilski v. Kappos*, 561 U.S. 593 (2010), forever shaping the patentability of business methods.

---

## EU Policy & Regulatory Alert: EU Mechanism for Foreign Investment Screening to Enter into Force in April

21 MAR 2019

Today, on 21 March 2019, the new Regulation establishing a framework for the screening of foreign direct investments into the Union was published in the Official Journal of the European Union (EU).

---

## Top of Mind: Litigation

20 MAR 2019

In this issue, our coverage of 10 big topics businesses have been thinking about this quarter.

---

## PFAS: in California, regulators put cleanup levels on hold, but announce major data hunt

7 MAR 2019

This data hunt will affect thousands of facilities, drinking water systems and private drinking water well owners.

---

## Explainability: where AI and liability meet

25 FEB 2019

Makers and users of AI face a new and interesting problem: what is the acceptable tradeoff between explanation and accuracy?

---

## Israel Group News

12 FEB 2019

### [ISRAEL GROUP NEWS](#)

In this issue, the rise of the Data Protection Officer, plus news and coming events.

---

## EU Policy & Regulatory Update - EU Adds Three Iranian Persons to EU Terrorist List

14 JAN 2019

---

On 8 January 2019, the Council of the European Union (EU) adopted Decision (CFSP) 2019/25 amending and updating the list of persons, groups and entities subject to Articles 2, 3 and 4 of Common Position 2001/931/CFSP.

---

### **Relying on "common sense" instead of prior art in evaluating the obviousness of pharmaceutical patents**

21 DEC 2018

A one-time aberration, or the start of a trend?

---

### ***Alice* in Wonderland: navigating the strange world of patenting AI**

21 DEC 2018

Like the bottle labeled DRINK ME, certain techniques can make the trip through the AI-patent rabbit hole more scalable.

---

### **Leading life science patent litigators join DLA Piper in New York**

21 DEC 2018

Michael Dougherty and Tony Pezzano have joined the firm's Intellectual Property and Technology practice as patent litigation partners in New York.

---

### **Top of mind: Litigation**

10 DEC 2018

Our coverage of big compliance, enforcement and litigation issues that businesses are thinking about this quarter.

---

### **Israel Group News**

24 OCT 2018

#### **ISRAEL GROUP NEWS**

In this issue, legal developments worldwide that affect this dynamic ecosystem.

---

### **CFIUS pilot program mandates declarations for certain non-controlling investments in critical technologies**

17 OCT 2018

The pilot program covers critical technologies in 27 industries.

---

### **Section 301 additional tariffs on imports of Chinese products: options for high tech and manufacturing companies**

3 OCT 2018

---

Additional tariffs of 10 percent or 25 percent have been imposed on three different lists of thousands of imports from China. Companies can request exclusion from these tariffs.

---

### **Supreme Court Corner Q3 2018**

27 SEP 2018

The court rules on recovery of lost foreign profits and ponders patentability issues in an invention's sale to a third party that is obligated to keep the invention confidential.

---

### **Intellectual Property and Technology News (Asia Pacific) September 2018**

27 SEP 2018

#### **[INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES](#)**

Intellectual Property and Technology News (Asia Pacific) is our annual publication designed to report on worldwide developments in intellectual property and technology law, offering perspectives, analysis and visionary ideas.

---

### **The tide turns: If your company is doing business in the US, it may soon be required to collect state sales taxes**

24 JUL 2018

Companies selling online products and services to customers in US states may soon be required to register, collect and remit taxes in those states.

---

### **eSignature and ePayment News and Trends**

23 JUL 2018

#### **[ESIGNATURE AND EPAYMENT NEWS AND TRENDS](#)**

This regular publication from DLA Piper aims to help companies identify significant news and legal developments impacting digital transactions.

---

### **eSignature and ePayment News and Trends**

29 JUN 2018

#### **[ESIGNATURE AND EPAYMENT NEWS AND TRENDS](#)**

In this issue, is your website ADA compliant? Plus news on federal and state law, federal and state regulatory activities, fresh judicial precedent and more.

---

### **Is your website ADA compliant? A brief look at the current legal status**

29 JUN 2018

Websites too face regulatory issues around compliance with the Americans with Disabilities Act and other rules involving

---



accessibility and accommodation.

---

## Pharmaceutical Trademarks 2018/2019 - Chapter: France

5 APR 2018

Like all trademarks, pharmaceutical trademarks are subject to general trademark rules regarding validity and use. Until recently, both French and European law required a trademark to be capable of graphical representation. This requirement allowed the registration of shapes, colours and sounds, but excluded signs such as smells. The European trademark law reform, comprising EU Directive 2015/2436 and the EU Trademark Regulation (2017/1001), deleted the graphical representation requirement from trademark law. This change marks a dramatic step forward in trademark law and could make it easier to register smells and other non-traditional trademarks.

---

## Regulation of medical devices - what is changing?

13 MAR 2018

After four years of deliberations, the new Medical Devices Regulation finally came into effect on 25 May 2017. This marks the commencement of a three-year transitional period for manufacturers of medical devices to update their policies and processes in order to distribute products in the EU market.

---

## Global Data Privacy Snapshot 2018: How does your organisation compare?

31 JAN 2018

Data protection is rising on the agenda globally: the past year has seen China introduce the PRC Cybersecurity Law, the introduction of Australia's mandatory Privacy Amendment (Notifiable Data Breaches) Act 2017, while the EU's long awaited General Data Protection Regulation is due to come in to force in May 2018.

---

## 2018 outlook for drugs and medical devices in China: regulatory reform fueled by innovation

18 JAN 2018

The year 2017 ended with a central government directive to reform the regulatory approval system for drugs and medical devices and a subsequent flood of CFDA changes and proposed changes to the system, and we should see further regulatory reform in 2018 as the Chinese government continues to encourage domestic innovation in this sector.

---

## Intellectual Property and Technology News (Asia Pacific) December 2017

7 DEC 2017

### [INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES](#)

Intellectual Property and Technology News (Asia Pacific) is our biannual publication designed to report on worldwide developments in intellectual property and technology law, offering perspectives, analysis and visionary ideas.

---

## Intellectual Property and Technology News (United States), Issue 23, Q3 2014

10 SEP 2014

---

## INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS SERIES

Our Intellectual Property and Technology News reports on worldwide developments in IP and technology law, offering perspectives, analysis and visionary ideas.

---

### **Distributing patent rights between affiliates: guidelines to support enforcement rights around the world**

16 NOV 2015

Considering a few issues at the outset when rights are distributed between Parent and Affiliate (or between multiple affiliates) may avoid difficulties in the future when a company wants to enforce patent rights.

---

## EVÈNEMENTS

### Récemment

#### **TopCo liability panel**

25 JUN 2019  
London

---

#### **New frontiers on the abuse of dominance**

18 JUN 2018  
Webinar

---

#### **Enforcement and compliance trends in today's life sciences environment**

26 APR 2018  
Webinar

---

## NEWS

---

### **DLA Piper announces launch of Artificial Intelligence practice**

14 MAY 2019

DLA Piper announced today the launch of its Artificial Intelligence practice, which will focus on assisting companies as they navigate the legal landscape of emerging and disruptive technologies, while helping them understand the legal and compliance risks arising from the creation and deployment of AI systems.

---

### **DLA Piper announces partnership promotions for 2019**

---

1 APR 2019

DLA Piper is proud to announce that 77 lawyers have been promoted to its partnership. The promotions are effective as of April 1, 2019 in the United States and May 1, 2019 for EMEA and Asia Pacific. The promotions were made across many of the firm's practice areas in 43 different offices throughout 20 countries.

---

### **DLA Piper enhances cross-border tax capability with new partner hire in Dublin**

26 FEB 2019

DLA Piper today announces the appointment of Maura Dineen as a Tax partner in the firm's newly opened Dublin office. This is the fifth partner hire for DLA Piper in Dublin in a month, following the announcements in January of Conor Houlihan (Finance & Projects), Éanna Mellett (Corporate), Mark Rasdale (Intellectual Property & Technology) and Ciara McLoughlin (Employment).

---

### **DLA Piper recognized as a leading private equity, venture capital and M&A firm in *PitchBook's* league tables**

19 FEB 2019

For the second consecutive year, DLA Piper was the only firm to rank as one of the top five most active law firms for private equity, venture capital and M&A deal volume in *PitchBook's* 2018 global league tables report.

---

### **DLA Piper conseille la Société d'aménagement Zenata dans son partenariat emblématique avec Saudi German Hospital Group**

29 MAY 2018

DLA Piper a conseillé la Société d'Aménagement Zenata (SAZ), l'entité en charge de l'aménagement global de l'Eco-Cité Zenata au Maroc, dans le cadre de sa signature d'une convention de développement et de gestion du pôle santé avec le groupe Saudi German Hospital (SGH).

---

### **DLA Piper named International Law Firm of the Year in Ukraine for fifth year running at The Legal Awards 2018**

24 MAY 2018

DLA Piper has been named International Law Firm of the Year in Ukraine at the 2018 Legal Awards, held by Yuridicheskaya Practika Publishing House. This is the fifth time the office has won the award.

---

### **DLA Piper announces partnership promotions for 2018**

3 APR 2018

DLA Piper is proud to announce that 62 lawyers have been promoted to its partnership. The promotions are effective as of 1 April 2018 in the United States and 1 May 2018 for EMEA and Asia Pacific. The promotions were made across many of the firm's practice areas in 42 different offices throughout 20 countries.

---

### **Businesses still not fully aware of Data Protection issues**

31 JAN 2018

DLA Piper has released its second Data Privacy Snapshot report, finding that once again, company global privacy programs

---

have gaps in meeting increasingly demanding global privacy principles. Significantly, it appears that many companies are falling short of data protection obligations under the General Data Protection Regulation (GDPR), which will start to apply from 25 May 2018.

---

### **Stephen Matthews joins DLA Piper's Litigation practice in New Jersey**

17 JAN 2018

DLA Piper announced today that Stephen Matthews has joined the firm's Litigation practice as a partner in the Short Hills, New Jersey, office.

---

### **DLA Piper advises Immunomedics on royalty funding and stock purchase agreements with Royalty Pharma which raised an aggregate of US\$250 million**

9 JAN 2018

DLA Piper represented Immunomedics, Inc., in the sale of tiered, sales-based royalty rights on global net sales of sacituzumab govitecan (IMMU-132) to Royalty Pharma for US\$175 million. Royalty Pharma has also purchased US\$75 million in common stock of Immunomedics, at US\$17.15 per share.

---

### **DLA Piper advises on the sale of shares in one of Egypt's fastest growing pharmaceutical companies**

9 NOV 2017

DLA Piper has advised Orchidia Pharmaceutical Industries (the "Company" or "Orchidia"), a leading ophthalmic generic medicine manufacturer and one of Egypt's fastest growing pharmaceutical companies, and Dr. Ossama Fouad Abbas, the founder, majority shareholder and Chairman of the Company, on the sale of a stake in the Company and two holding companies incorporated in Cyprus to Egyptian-American Enterprise Fund (EAEF).

---